Evixapodlin exhibits an ability to increase the production of IFN-γ and Granzyme B in both CD8+ and CD4+ T cells in individuals with chronic hepatitis B (CHB). Additionally, Evixapodlin enhances the frequency of Granzyme B-positive cells among HBV-specific CD8+ and CD4+ T cells.[1]

Evixapodlin (10-50 mg/kg; intraperitoneal injection, daily, for 6 days) treatment results in over 90% occupancy of the PD-L1 target on tumor cells. Evixapodlin effectively suppresses tumor growth in a mouse colorectal tumor model (MC38) that expresses human PD-L1.[1]